Chiasma Raises $33.8M To Continue Acromegaly Drug Development

December 30, 2014 | The Israeli company Chiasma raised $33.8 million in a $563 million funding round, according to regulatory findings. The announcement comes some months after a $595 million commercialization deal for the company feel through. Chiasma’s main product, called oral octreotide was developed to treat acromegaly, a disorder that results from the excess growth of hormones. Current investors participating in the funding round include: MPM Capital, Abingworth, 7-Med Health Ventures LP, ARCH Venture Partners and F2 and F3 Ventures.